Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology. He entered college at 16 years of age, and medical school at age 19 on full scholarships. While in medical school he obtained a degree in Electrical Engineering, Magna Cum Laude with distinction, and graduated from Medical School, Summa Cum Laude, at 23 years of age. Dr. Weiss is the author of more than 100 publications, including 20 books, holds more than 20 U.

S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two profitable companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss' inventions worldwide.

Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment to successfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions. Dr. Weiss performed the first retinal stem cell surgery in the world in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world; The Neurologic Stem Cell Treatment Study; The Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study; and The Alzheimer's, Cognitive Impairment and Autism Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH and listed on ClinicalTrials.gov.